Zinman, Bernard
Nauck, Michael A.
Bosch-Traberg, Heidrun
Frimer-Larsen, Helle
Ørsted, David D.
Buse, John B.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
https://doi.org/10.2337/dc16-2747
Liraglutide and Glycaemic Outcomes in the LEADER Trial
https://doi.org/10.1007/s13300-018-0524-z
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
https://doi.org/10.2337/dc18-1094
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial (Results)
https://doi.org/10.2337/dc17-1956
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial (Results)
https://doi.org/10.2337/dc19-0415
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial (Results)
https://doi.org/10.2337/dc17-1825
Liraglutide Effects in Insulin-Treated Patients in LEADER
https://doi.org/10.2337/db18-438-p
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
https://doi.org/10.1016/j.ahj.2013.07.012
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
https://doi.org/10.2215/cjn.11881019
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (Results)
https://doi.org/10.2337/dc20-1622
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial (Results)
https://doi.org/10.2337/dc20-0437
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (Results)
https://doi.org/10.2337/dc19-2251
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
https://doi.org/10.2337/dc17-2677
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 (Results)
https://doi.org/10.2337/dci19-0067
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 13 September 2018
First Online: 3 November 2018